# Ozempic Vs. Glucose Monitors (feat. Sharam Fouladgar-Mercer) #685

Page: https://stenobird.com/podcast/biohacking-news-by-zestology-173365/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685
Text version: https://stenobird.com/podcast/biohacking-news-by-zestology-173365/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685.md
Podcast: [Biohacking News by Zestology](https://stenobird.com/podcast/biohacking-news-by-zestology-173365)
Published: 2026-03-30T01:00:00+00:00
Episode link: https://zestology.libsyn.com/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685
Audio file: https://traffic.libsyn.com/secure/zestology/685_BION_Sharam_Fouladgar_Libsyn.mp3?dest-id=270303
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/biohacking-news-by-zestology-173365/episodes/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685
Duration seconds: 1970

## Resource

Yet more GLP1 news this week. People regain on average 60% of their lost weight within a year of stopping GLP-1 drugs — and the regained weight may be disproportionately fat rather than muscle. So are a tool that biohackers have known about for years - CGMs - the answer? Sharam Fouladgar-Mercer is the co-founder of Signos, the first ever FDA-cleared glucose system for weight management. Follow Sharam Fouladgar-Mercer on LinkedIn.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/biohacking-news-by-zestology-173365/episodes/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/biohacking-news-by-zestology-173365/ozempic-vs-glucose-monitors-feat-sharam-fouladgar-mercer-685.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.